Immunic (NASDAQ:IMUX) announced positive results from the part C portion of its Phase 1 clinical trial of IMU-856 in patients with celiac disease. The company believes that this data set provides initial clinical proof...
Magenta Therapeutics (NASDAQ:MGTA) and closely-held Dianthus Therapeutics entered into a definitive merger agreement to combine the companies in an all-stock transaction that is expected to close in the third quarter of...
PharmaJet appointed Nathalie Landry as chief scientific officer to provide strategic leadership and ensure the company’s clinical and scientific programs align with its global commercial expansion. PharmaJet’s pipeline...
NeuroSense Therapeutics (NASDAQ:NRSN) reported positive preliminary results from a novel biomarker study conducted to evaluate the potential of its combination platform therapy for the treatment of Parkinson’s...
Profound Medical’s (NASDAQ:PROF; TSX:PRN) TULSA procedure was featured in four presentations at the American Urological Association (AUA) annual meeting that reinforced its safety, efficacy and durability, further...
Dawson James upgraded Can-Fite BioPharma (NYSE American, TASE:CANF) to “buy” from “neutral” with a $6 price target. The stock closed at $1.74 on April 28. Analyst Jason Kolbert writes that the stock is reaching new lows...
Kiora Pharmaceuticals (NASDAQ:KPRX) presented preliminary results from an ongoing clinical trial, showing that its investigational drug, KIO-301, has the potential to restore light perception in patients who are blind...
Raymond James initiated coverage of WELL Health Technologies (TSX:WELL) with an “outperform” rating and price target of $8.50 (Canadian). The stock closed at $5.46 on April 27. WELL Health operates a hybrid care...
Avidity Biosciences (NASDAQ:RNA) reported positive topline data from the Phase 1/2 MARINA clinical trial of AOC 1001 for the treatment of myotonic dystrophy type 1 (DM1), an underrecognized, progressive and often fatal...
Cantor Fitzgerald launched coverage of Disc Medicine (NASDAQ:IRON) with an “overweight” rating and 12-month price target of $45. The stock closed at $32.24 on April 27. Disc Medicine is a clinical-stage...
Research Capital remains bullish on the ability of Theralase Technologies’ (TSXV:TLT; OTCQB:TLTFF) Ruvidar to treat BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), given updated data released in the fourth...
SAB Biotherapeutics (NASDAQ:SABS) reported positive top-line results from the Phase 3 National Institutes of Health’s ACTIV-2 clinical trial that assessed SAB-185 in non-hospitalized people with COVID-19 who were at...